Frank Meyskens - Irvine CA, US Anne Simoneau - Long Beach CA, US Eugene Gerner - Tucson AZ, US
International Classification:
A61K031/198
US Classification:
514/564000
Abstract:
The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.
Alpha-Difluoromethylornithine(Dfmo) Suppresses Polyamine Levels In The Human Prostate
Frank Meyskens - Irvine CA, US Anne Simoneau - Long Beach CA, US Eugene Gerner - Tucson AZ, US
International Classification:
A61K031/198
US Classification:
514/564000
Abstract:
The present invention concerns a method for treating and/or inhibiting prostate cancer in a patient comprising administering -difluoromethylornithine (DFMO) in an amount and duration sufficient to stabilize or reduce the amount of polyamine produced by the hyperplastic cells, wherein said polyamine is spermine, spermidine or a combination of spermine and spermidine. Methods of administration, dosing, and combinational therapies are described.
Compositions of matter and methods wherein chalcone and flavone derivatives are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compounds of the invention include 2′-hydroxy-4,4′,6′-trimethoxychalcone (Flavokawain A).